$46.00
1.30%
Nasdaq, Fri, Sep 27 2024
ISIN
US4380831077
Symbol
FIXX
Sector
Industry

Homology Medicines, Inc. Stock price

$46.00
+8.18 21.63% 1M
+29.83 184.48% 6M
+35.06 320.32% YTD
+25.48 124.17% 1Y
-108.80 70.28% 3Y
-279.08 85.85% 5Y
-289.88 86.30% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
+0.59 1.30%
ISIN
US4380831077
Symbol
FIXX
Sector
Industry

Key metrics

Market capitalization $547.64m
Enterprise Value $459.84m
P/E (TTM) P/E ratio negative
P/B ratio (TTM) P/B ratio 16.25
Revenue growth (TTM) Revenue growth -100.00%
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-66.54m
Cash position $107.65m
EPS (TTM) EPS $-23.00
P/E forward negative
Short interest 0.04%
Show more

Is Homology Medicines, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Homology Medicines, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Homology Medicines, Inc. forecast:

5x Buy
100%

Analyst Opinions

5 Analysts have issued a Homology Medicines, Inc. forecast:

Buy
100%

Financial data from Homology Medicines, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
- -
-
100%
- Direct Costs 0.38 0.38
84% 84%
-
-0.38 -0.38
212% 212%
-
- Selling and Administrative Expenses 23 23
15% 15%
-
- Research and Development Expense 42 42
56% 56%
-
-66 -66
46% 46%
-
- Depreciation and Amortization 0.38 0.38
84% 84%
-
EBIT (Operating Income) EBIT -67 -67
47% 47%
-
Net Profit -65 -65
51% 51%
-

In millions USD.

Don't miss a Thing! We will send you all news about Homology Medicines, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Homology Medicines, Inc. Stock News

Neutral
GlobeNewsWire
6 months ago
BEDFORD, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX) today announced that it declared a distribution to its common stockholders of record as of the close of business on March 21, 2024 of the right to receive one contingent value right (CVR) for each outstanding share of Homology common stock held by such stockholder as of such record date. The payment date ...
Neutral
Business Wire
7 months ago
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Homology Medicines, Inc. (NasdaqGS: FIXX) with Q32 Bio Inc. Under the terms of the proposed transaction, Homology shareholders will end up owning approximately 25% of the combined company, subject to possible ad...
Neutral
PRNewsWire
8 months ago
NEW ORLEANS , Jan. 26, 2024 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
More Homology Medicines, Inc. News

Company Profile

Homology Medicines, Inc. operates as a technology platform to design and develop treatments to address rare diseases at the genetic level. It develops genetic medicines by translating proprietary, next generation gene editing and gene therapy technologies into novel treatments for patients with rare diseases. The company was founded by Saswati Chatterjee in 2015 and is headquartered in Bedford, MA.

Head office United States
CEO Jodie Morrison
Employees 7
Founded 2015
Website www.q32bio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today